8-K – 2026-02-02 – tm264623d1_8k.htm

false
IDEXX LABORATORIES INC /DE
0000874716

0000874716

2026-02-02
2026-02-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

 

 

 

UNITED
STATES

SECURITIES
AND EXCHANGE COMMISSION

Washington,
D.C. 20549

 

 

 

FORM
8-K   

CURRENT
REPORT 

 

Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date
of report (Date of earliest event reported): February 2, 2026

 

 

IDEXX
LABORATORIES, INC.

(Exact
name of registrant as specified in its charter)

  

Delaware
 
000-19271
 
01-0393723

(State
or other jurisdiction
 
(Commission
File Number)
 
(IRS
Employer Identification No.)

of
incorporation)
 
 
 
 

 

One IDEXX Drive , Westbrook , Maine
04092

(Address
of principal executive offices)

(ZIP
Code)

 

207 . 556.0300

(Registrant's
telephone number, including area code)

 

Not
Applicable

(Former
name or former address, if changed since last report)

 

Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): 

 

 
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities
registered pursuant to Section 12(b) of the Act:

 

Title
of each class
 
Trading
Symbol(s)
 
Name
of each exchange on which registered

Common
Stock, $0.10 par value per share
 
IDXX
 
NASDAQ
Global Select Market

  

Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company  ¨

 

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨

 

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On February 2, 2026, IDEXX Laboratories, Inc.
(the “Company”) announced its financial results for the quarter and year ended December 31, 2025. The full text of the
press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

In accordance with general instructions to Form 8-K,
the information in this Form 8-K and the Exhibit 99.1 attached hereto is being furnished under Item 2.02 and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d)           Exhibits

 

The following exhibit relating to Item
2.02 shall be deemed to be furnished, and not filed.

 

Exhibit No.
Description of Exhibit

 

99.1 Press Release entitled “IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results,”
issued by the Company on February 2, 2026.

 

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

  1  

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 
IDEXX LABORATORIES, INC.

 
 

Date: February 2, 2026
By:
/s/ Andrew Emerson

 
 
Andrew Emerson

 
 

Executive Vice President,

Chief Financial Officer and Treasurer

 

  2